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Abstract
Background: Germline mutations in p53 are associated with the Li-Fraumeni Syndrome which is characterized by
childhood cancers, including pediatric adrenal cortical carcinomas and early onset breast cancer. The high
incidence of adrenal cortical carcinomas in southern Brazil is mostly attributed to the R337H mutation in TP53.T h e
relatively high population frequency of this mutation in southern Brazil, along with the clustering of early onset
breast cancer in Li-Frameni families, suggests this mutation may also be a low-penetrance breast cancer
susceptibility polymorphism.
Methods: We undertook this study to evaluate the frequency of the R337H mutation in breast cancer patients
from Rio de Janeiro, Brazil. R337H mutation status was determined in 390 unselected breast cases and 324 controls
identified from clinics in Rio de Janeiro, Brazil using a PCR-based assay.
Results: Two of the breast cancer cases (0.5%) and none of the controls carried the mutation. Both cases had an
early age at diagnosis (< 40 years old) and a family history of breast and other cancers.
Conclusions: These data suggest genetic screening of young onset breast cancer patients should include testing
for the R337H mutation.
Keywords: Brazil, Breast cancer, TP53 mutation, Adrenal cortical carcinomas
Introduction
Germline mutations in p53 are associated with Li-Frau-
meni Syndrome which is characterized by childhood
cancers and early onset breast cancer [1]. The spectrum
of tumors includes soft tissue sarcomas, osteosarcomas,
breast cancers and pediatric adrenal cortical carcinomas.
It has been reported that the incidence of pediatric
adrenal cortical carcinomas in southern Brazil is 10-15
times higher that the incidence in the United States [2].
Studies by Ribeiro et al. have shown that the majority of
adrenal cortical carcinoma cases in southern Brazil are
attributed to one specific germ-line point mutation in
exon 10 at codon 337 (CGC ® CAC) of TP53 resulting
in an arginine-to-histidine amino acid substitution
(R337H) [3].
Initially, it was believed that this mutation did not
confer an increased risk of developing additional cancers
[4]; however, various groups have suggested that this
mutation also increases the risk of breast cancer in
women living in southern Brazil [5-8]. Given that Li-
Fraumeni syndrome patients display higher than normal
rates of breast cancer, we undertook this study to evalu-
ate the frequency of the R337H mutation in a case-con-
trol study of breast cancer conducted in Rio de Janeiro,
Brazil.
Methods
Study design
The study was conducted in Rio de Janeiro, Brazil
between February 2003 and September 2005. In Brazil,
patients with breast cancer are treated for in both public
and private settings. To ensure that patients from a wide
range of ethnic and social backgrounds were included in
the current study, patients were recruited from both a
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any medium, provided the original work is properly cited.public hospital (Hospital of the Federal University of Rio
de Janeiro) and from two private medical clinics (The
Centre of Tumor Treatment, Botafogo, Rio de Janeiro,
Brazil and the clinic of Roberto Vieira in Copacabana,
Rio de Janeiro) all of which provide oncology services.
Protocols were approved by the institutional review
boards at all the participating centers.
Study population
Potential case subjects were approached to participate in
the study during an out-patient visit to the medical
oncology clinic, or during hospital admission. Cases
were women between 20 and 60 years of age and who
had been diagnosed with invasive breast cancer between
1978 and 2005. In total, 382 women were approached to
participate, of whom 381 agreed (one women declined
because she did not wish to receive genetic testing).
There were 195 patients recruited from the public hos-
pitals and 186 patients recruited from the private clinics.
Three cases had a past history of other cancers (two
lymphomas and one melanoma). Potential control sub-
jects were women without a diagnosis of breast cancer,
but who sought medical attention for another condition.
Controls were derived from the same public hospital
and medical clinics and as the cases. All controls were
in-patients in medical and surgical wards and were
being treated for a range of non-cancerous conditions.
In total, 486 controls were recruited (no potential con-
trol declined). All women provided written informed
consent to participate in the study.
Data and sample collection
All of the study subjects participated in a structured
interview that collected information about reproductive,
hormonal, and lifestyle exposures. Women were
requested to provide a sample of blood for genetic test-
ing and to provide details about their family history of
cancer.
Mutation analysis
DNA was extracted from peripheral blood leukocytes
using Puregene DNA Isolation Kit (Gentra Systems,
Minneapolis, USA). Mutation analysis was performed on
390 cases and 324 controls using the tetra-primer ampli-
fication refractory mutation system (ARMS) [9]. Two
allele-specific amplicons are generated using two pairs
of primers. One pair produces an amplicon that repre-
sents the wildtype allele, and the other corresponding to
the mutant allele. These two amplicons differ in length,
which allowing for discrimination by agarose gel electro-
phoresis. All mutations detected were confirmed by
direct sequencing [BigDye Terminator v.3.1 Cycle
Sequencing Kit, and 3130XL Genetic Analyzer (Applied
BioSystems)] according to manufacturer’si n s t r u c t i o n s .
Primers used for assay and sequencing are available
upon request.
Results
DNA from a total of 716 study subjects was tested for
the R337H mutation in TP53. The mean age at diagno-
sis of cases was 46 years old (range 25-66) and the
mean age at interview of the controls was 40 years old
(range 19-63). There were 87 cases that were diagnosed
at or before age 40. Of the 390 cases tested, we identi-
fied two cases with a R337H mutation (mutation fre-
quency 0.5%). Pedigrees for the two cases are displayed
in Figure 1 and 2. None of the 324 controls were found
to carry this mutation. The prevalence of mutations
among women ≤ 4 0y e a r so fa g ew a s2 . 3 % .T h ea g e so f
diagnoses for the two cases with the R337H mutation
were 35 and 39. The first breast cancer case with a
R337H mutation was diagnosed with breast cancer at
age 35. Her mother was diagnosed with breast cancer at
age 50 and her father had a diagnosis of laryngeal can-
cer at age 55. Her maternal grandfather had a diagnosis
of prostate cancer at age 85. The second breast cancer
case was diagnosed at age 39 with bilateral breast can-
cer. Her mother had a diagnosis of nonmelanoma skin
cancer at age 74 and her maternal aunt had a diagnosis
of breast cancer at age 30. Her father and paternal uncle
were diagnosed with gastric cancer at age 65 and 52,
respectively while a different paternal uncle developed
prostate cancer at age 70. A paternal aunt was diag-
nosed of uterine cancer at age 62.
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Figure 1 Pedigree for breast cancer case diagnosed at age 35
with a TP53 R337Hmutation.
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Our study suggests that the prevalence of the TP53
R337H mutation in breast cancer patients diagnosed in
clinics of Rio de Janeiro, Brazil is low. Only two of the
390 cases were found to carry this mutation (~0.5%)
with an age of diagnosis of 35 and 39 (bilateral breast
cancer). This estimate is substantially lower than that
obtained in previous studies conducted in southern Bra-
zil (range 2.4-11%) which included study participants
f r o mR i od eJ a n e i r o ,S a oP a o l oa n dP o r t oA l e g r e[ 5 , 8 ] .
Sao Paolo and Porto Alegre are 442 km and 1546 km
from Rio de Janeiro, respectively. They did not evaluate
frequency based on city; however, all three cities are
located on the eastern side of Brazil and close to the
Atlantic ocean. Despite similarities in geographic regions
and the mutation of interest, these studies were substan-
tially different with respect to the selection of their
study populations and may explain why our mutation
frequency was substantially lower. For example, the cur-
rent study included unselected cases of breast cancer,
while the two other studies included subjects with
families suggestive of Li-Fraumeni syndrome [5,8].
Achatz et al. screened 45 Brazilian subjects from unre-
lated families with cancer histories suggestive of Li-
Fraumeni syndrome and 53 healthy subjects for the
R337H mutation [8]. They found a TP53 mutation in 13
cases, six of which were the R337H mutation. None of
the 53 healthy subjects carried the mutation. In addi-
tion, the most common type of tumor in these families
was that of the breast (~30.4%) [3]. In additional studies,
the same researchers identified the R337H mutation in
two out of 750 healthy women (0.3%) enrolled in a
breast screening program in Porto Alegre, southern Bra-
zil [7]. Both cases had a family history of cancer but did
not match the Li-Fraumeni syndrome clinical profile.
Assumpcao et al. estimated the prevalence of this
mutation in 123 breast cancer cases and 223 age-
matched controls [5]. Three of the cases (2.4%) and
none of the controls were carriers of the R337H muta-
tion (P = 0.04). All three cases had an early age at diag-
nosis (range 19-44 years old) and two of the three cases
had a family history suggestive of Li-Fraumeni syn-
drome. Interestingly, all three tumors showed loss of
heterozygosity of the mutant allele versus the wild-type
allele in contrast to pediatric adrenal cortical carcinomas
that normally retain the mutant allele [3,10]. Given that
not all families with the R337H mutation present with
other cancers, the authors tested for the presence of
other genetic variants within TP53 (R72P and ins16)
and MDM2 (SNP309) that have been reported to affect
tumor susceptibility and age at onset in R337H muta-
tion carriers, respectively [11-14]. Two of the cases were
heterozygous both the TP53 SNPs, while the third
patient was homozygous for both R72P. Two of the
cases also carried the MDM2 polymorphism. Based on
these findings, it has been suggested that the R337H
mutation in combination with other SNPs may affect
p53 function and ultimately, breast cancer
predisposition.
Functional analysis has shown the mutant p53 protein
to be pH-sensitive and may adopt a mutant phenotype
only under particular physiological conditions [3,10].
Further, the authors have shown that the mutated
tumor cells demonstrate a loss of heterozygosity of the
wild-type allele with retention of the mutant allele and
accumulation of mutant p53 protein in the nucleus. The
penetrance of adrenal cortical carcinomas among car-
r i e r so ft h i sm u t a t i o ni s9 . 9 %( 9 5 % C I8 . 7 - 1 1 . 1 % )b yt h e
age of 12 years [4]. The frequency of this mutation in
southern Brazil has been estimated to be approximately
0.2%-0.3% [7]. Due to this high population frequency
the R337H mutation, along with the high incidence of
adrenal cortical carcinomas, has led to the implementa-
tion of screening all newborns in the state of Parana in
southern Brazil [15].
Strengths of the current study include the large sam-
ple size and extensive information on family history. All
the participants in this study were recruited from public
and private clinics in Rio de Janeiro, Brazil and thus our
results are generalizeable to population of Brazil.
Conclusions
We have previously identified a BRCA1 or BRCA2
mutation in 2.3% of women with breast cancer using
the same study population [16]. The frequency of the
BRCA mutation is substantially higher compared with
the R337H mutation and thus, may play a more impor-
tant role in predisposing to breast cancer in this South
American population. Nonetheless, given the high popu-
lation frequency of the R337H mutation in southern
Brazil, this might have an important implication with
respect to genetic screening of breast-cancer
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Figure 2 Pedigree for breast cancer case diagnosed at age 39
with a TP53 R337Hmutation.
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determine if this mutation should be added to existing
panel of mutations when screening individuals with a
family history.
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